FDA Places Clinical Hold On Ocugen's Late-Stage COVID-19 Vaccine Trial

The FDA has placed a clinical hold on Ocugen Inc OCGN Phase 2/3 immuno-bridging and broadening study for COVAXIN (BBV152) OCU-002. 

Posted In: BriefsCOVID-19 CoronavirusCOVID-19 VaccineBiotechNewsPenny StocksHealth CareSmall CapFDAGeneral